Teresa L. Young - 03 Feb 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
EVP, Chief Commercial & Strategy Officer
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for Teresa L. Young
Issuer symbol
MCRB
Transactions as of
03 Feb 2023
Net transactions value
$0
Form type
4
Filing time
07 Feb 2023, 16:43:24 UTC
Previous filing
08 Feb 2022
Next filing
31 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Restricted Stock Units Award $0 +42,500 $0.000000 42,500 03 Feb 2023 Common Stock 42,500 Direct F1, F2
transaction MCRB Restricted Stock Units Award $0 +85,000 $0.000000 85,000 03 Feb 2023 Common Stock 85,000 Direct F1, F3
transaction MCRB Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 03 Feb 2023 Common Stock 85,000 $5.50 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
F3 The restricted stock units will vest and settle as to 100% of the restricted stock units on August 3, 2024.
F4 The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

EVP, Chief Commercial & Strategy Officer